XML 44 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Detail)
1 Months Ended 12 Months Ended 24 Months Ended 27 Months Ended
Aug. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
segment
item
Dec. 31, 2016
USD ($)
item
Dec. 31, 2017
USD ($)
item
Dec. 31, 2013
Fair Value Measurements          
Number Of Operating Segments | segment   1      
Assets measured at fair value levels 2 or 3   $ 0 $ 0 $ 0  
Liabilities measured at fair value levels 2 or 3   0 0 0  
Carrying value of cash held in money market fund   $ 121,900,000 $ 38,000,000 121,900,000  
Impairment of Long-Lived Assets          
Number of long-lived assets determined to be impaired | item   0 0    
Assets held for sale   $ 0 $ 0 $ 0  
Maximum          
Share-based Compensation          
Expected term   10 years      
Pfizer | License Agreement          
Revenue Recognition          
Milestone revenue $ 20,000,000 $ 0 $ 0    
Number of milestones met | item       0  
Pfizer | License Agreement | Up-Front Payment Arrangement          
Revenue Recognition          
Recognition period of up-front payment         1 year 6 months